Oculus Innovative Sciences Announces Preliminary Results From 40-Patient Feasibility Study For Treatment Of Acne With The Microcyn(R) Technology

Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), a healthcare company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, announced that preliminary results from its U.S.

See the article here:
Oculus Innovative Sciences Announces Preliminary Results From 40-Patient Feasibility Study For Treatment Of Acne With The Microcyn(R) Technology

Related posts:

1. Oculus Innovative Sciences Announces Preliminary Results From 40-Patient Feasibility Study for Treatment of Acne With Enhanced Microcyn Hydrogel… Company to Explore Partnerships for Newly Enhanced Microcyn Hydrogel, Targeting...
2. AmDerma Pharmaceuticals Exercises Option to License Rights to Oculus Innovative Sciences Microcyn(R)-Based Acne Drug Candidate PETALUMA, Calif. ...
3. CLRS Technology Announces FDA Clearance CLRS Technology Corporation announced it received over-the-counter (OTC) clearance from...
4. Onset Therapeutics Announces Results Of BenzEFoam™ Skin Hydration Study Onset Therapeutics, a specialty pharmaceutical company focused in dermatology, today...
5. Elorac, Inc. Announces Clinical Results Of Carbamide Peroxide Studies For The Treatment Of Acne Elorac, Inc., a rapidly growing specialty pharmaceutical company focused on...

Leave a comment

Name (required)

E-mail (required)

URI

Your Message